Thus, fast improvement of the erythrodermic ichthyosis and eczema lesions using a combination of Dupilumab/Guselkumab indicate clinical evidence and proof‐of‐principle for an effective, safe, well‐tolerated treatment of CIE using anti‐IL‐23 and anti‐IL‐4 therapy in combination, if needed. This evidence concerns the gene IL23A and congenital non-bullous ichthyosiform erythroderma.